On April 28, 2025, Ascentage Pharma presented results from five preclinical studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The presentations featured data on olverembatinib (HQP1351), lisaftoclax (APG-2575), APG-2449, APG-5918, and AS03157.
Notably, the combination of olverembatinib and lisaftoclax demonstrated strong synergistic effects in preclinical models of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). These findings suggest enhanced therapeutic outcomes for these key drug candidates.
The encouraging data from these investigational assets reinforce Ascentage Pharma's innovative pipeline and are expected to further catalyze clinical development. The company continues to advance its programs to bring more treatment options to patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.